An Open-label, Randomised, Single Dose, Parallel-group Phase I Study to Investigate the Pharmacokinetic Properties of 200 mg Nevirapine Extended Release Tablets When Administered Orally as 2x100 mg Tablets or as 4x50 mg Tablets in Healthy Male Volunteers
Latest Information Update: 22 Jul 2014
Price :
$35 *
At a glance
- Drugs Nevirapine (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 22 Jul 2014 New trial record